This resulted in an upregulation of T cell chemo-attractants such as Cxcl9/10/11 and antigen presentation genes including H2-d/k1, Ciita, and B2m (Fig. 1) [7], thus demonstrating how even neoantigen-high KRAS-mutant tumours can escape the adaptive immune response [7, 8, 40]. The gene discussed is KRAS; the disease is neoplasm.